Objective: To determine whether a weighted versus unweighted balloon catheter achieved a shorter first stage of labor.
Methods: This was a randomized trial of patients undergoing induction with Bishop score <4. Women were randomized to weighted balloon catheter with 1000 mL fluid bag or unweighted catheter taped to the thigh.
Results: A total of 60 women were randomized. The time from balloon catheter insertion until discontinuation was significantly longer in the unweighted group 4.62 ± 0.65 h versus 1.59 ± 0.2 h in the weighted group (p = 0.001). This resulted in longer cervical ripening/first stage of labor in the unweighted (18.52 ± 0.96 h) versus weighted group (15.3 ± 0.99 h) (p = 0.025). The unweighted balloon catheter had a shorter first stage of labor as gravidity increased (p = 0.007) and as race went from white to non-white (p = 0.003). There was no difference in perceived pain after balloon insertion (p = 0.0942), or Bishop score after balloon discontinuation (p = 0.1661).
Conclusion: The total time from cervical ripening to the end of the first stage of labor is significantly shortened with the weighted balloon catheter.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/14767058.2011.587063 | DOI Listing |
J Vasc Surg
January 2025
Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, University of Pennsylvania, Philadelphia, PA; Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA.
Background: PAD affects >12 million Americans and poses significant financial burdens on patients, but the relationship between delayed/forgone (D/F) care and resource use in this population is unknown. We sought to assess the relationship between D/F care, resource use, and health care expenditures among patients with PAD.
Methods: Adults with PAD in the US were identified in the Medical Expenditure Panel Survey for years 2007-2017.
Ann Surg Oncol
December 2024
Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
Background: Although high treatment costs of breast cancer care are well documented, the relationship between delayed/forgone (D/F) care and resource utilization among patients with breast cancer is unknown. This study sought to investigate the relationship between D/F care, resource use, and healthcare expenditures among patients with breast cancer.
Methods: Data on adult female patients with breast cancer were obtained from the Medical Expenditure Panel Survey to assess resource utilization and expenditures in the United States from 2007 to 2017.
Curr Med Res Opin
January 2025
Department of Epidemiology, Indiana University, Indianapolis, IN, USA.
Objective: Chronic cough (CC) symptoms can persist as refractory or unexplained CC (RCC). We sought to characterize the clinical and economic burden of RCC.
Methods: In this retrospective US cohort study using data from Optum's de-identified CDM Database (01/2015-03/2022), CC was identified as ≥1 CC diagnosis or ≥3 cough events (with ≥8 weeks and ≤120 days between the first and third events and ≥3 weeks between any two events).
Ann Rheum Dis
November 2024
Department of Internal Medicine, Hospital Cochin, AP-HP, Paris, France
Background: The PEXIVAS (Plasma exchange and glucocorticoids in severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis) trial showed that a reduced-dose glucocorticoid regimen (redGC) was non-inferior to a standard-dose regimen (standGC) with respect to death or end-stage kidney disease (ESKD) in patients with ANCA-associated vasculitis (AAV). However, the primary endpoint did not include disease progression or relapse, cyclophosphamide was the main induction therapy and rituximab (RTX)-treated patients tended to have a higher risk of death or ESKD with redGC. We aimed to evaluate the real-world use of redGC.
View Article and Find Full Text PDFInt Urol Nephrol
November 2024
Analysis, and Evaluation, Henry Ford Health, VUI Center for Outcomes Research, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!